¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inverse agonist"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® agonist ÇÑ±Û ÀÛ¿ëÁ¦, ÀÛ¿ë±Ù
¼³¸í   
  1. ¼ö¿ëü¿Í °áÇÕÇÏ¿© ÃÖ´ëÀÇ ¾à¸®ÀÛ¿ëÀ» ¹ßÇöÇϴ ȭÇй°ÁúÀ» ¸»ÇÑ´Ù. ¼ö¿ëü¿¡ Æ¯ÀÌÇϰԠģȭ¼ºÀ» °¡Áö°í ÀÖ´Ù. »ýü ¾È¿¡¼­ »ý»êµÇ´Â ³»ÀμºÀΠ°Í°ú »ýü ¹Û¿¡¼­ Åõ¿©µÇ´Â ¿ÜÀμºÀΠ°ÍÀÌ ÀÖ´Ù. ºÎºÐ ÀÛ¿ëÁ¦´Â ¼ö¿ëü¿Í °áÇÕÇØµµ 100%ÀÇ ¾à¸®ÀÛ¿ëÀ» ¹ßÇöÇÏÁö´Â ¾ÊÀ¸¸ç ¿ë·®À» Áõ°¡½ÃÄѵµ È¿°ú´Â Ä¿ÁöÁö ¾Ê´Â´Ù. 2. ÇغÎÇп¡¼­´Â ÁÖ°¡ µÇ¾î ¿òÁ÷À̴ ±ÙÀ°ÀÇ ¹«¸®
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inverse agonist
    ¿ªÀÛ¿ëÁ¦
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agonist
    1. ÀÛ¿ëÁ¦ 2. ÀÛ¿ë±Ù
  • beta2-agonist
    º£Å¸2ÀÛ¿ëÁ¦
  • cholinergic agonist
    Äݸ°¼ºÀÛ¿ëÁ¦
  • dopamine agonist
    µµÆÄ¹ÎÀÛ¿ëÁ¦
  • GnRH agonist
    »ý½Ä»ùÀÚ±ØÈ£¸£¸ó¹æÃâÈ£¸£¸óÀÛ¿ëÁ¦
  • gonadotropin-releasing hormone agonist
    »ý½Ä»ùÀÚ±ØÈ£¸£¸ó¹æÃâÈ£¸£¸óÀÛ¿ëÁ¦
  • muscarinic agonist
    ¹«½ºÄ«¸°ÀÛ¿ëÁ¦
  • opioid agonist
    ¾ÆÆíÀ¯»çÀÛ¿ëÁ¦
  • inverse
    ¿ª-
  • inverse interpolation
    ¿ªº¸°£¹ý
  • inverse lymph node
    ¿ªÀ§¸²ÇÁÀý
  • inverse occlusion
    ¹Ý´ë°¡¸²
  • inverse psoriasis
    ºÎÀ§¹Ù²ñ°Ç¼±
  • inverse radiotherapy
    µµÄ¡¹æ»ç¼±Ä¡·á
  • inverse response
    ¿ª¹ÝÀÀ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gonadotropin releasing hormone agonist agonist
    »ý½Ä»ùÀÚ±ØÈ£¸£¸óºÐºñÈ£¸£¸óÀÛ¿ëÁ¦
  • inverse
    ¿ª-
  • agonist
    1.ÀÛ¿ëÁ¦, 2.ÀÛ¿ë±Ù
  • beta2 agonist
    º£Å¸2ÀÛ¿ëÁ¦
  • dopamine agonist
    µµÆÄ¹ÎÀÛ¿ëÁ¦
  • GnRH agonist
    (¢¡gonadotropin releasing hormone agonist) »ý½Ä»ùÀÚ±ØÈ£¸£¸óºÐºñÈ£¸£¸óÀÛ¿ëÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inverse agonist
    ¿ªÀÛ¿ëÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agonist
    ÀÛ¿ëÁ¦, ÀÛ¿ë±Ù
  • cholinergic agonist
    Äݸ°¼ºÃËÁøÁ¦
  • muscarinic agonist
    ¹«½ºÄ«¸°ÀÛ¿ëÁ¦
  • opioid agonist
    ¾ÆÆíÀ¯»çÀÛ¿ëÁ¦
  • inverse eruption
    Ä¡¾Æ¿ª»ý
  • inverse
    ¿ª-
  • inverse interpolation
    ¿ªº¸°£¹ý
  • inverse matrix
    ¿ªÇà·Ä
  • inverse occlusion
    ¹Ý´ë°¡¸²
  • inverse psoriasis
    ÀÚ¸®¹Ù²Þ°Ç¼±, ¿ªÀ§°Ç¼±
  • inverse radiotherapy
    µµÄ¡¹æ»ç¼±Ä¡·á
  • inverse response
    ¿ª¹ÝÀÀ
  • inverse substitution
    ¿ªÄ¡È¯
  • inverse lymph node
    ¿ªÀ§¸²ÇÁÀý
  • inverse square law
    ¿ªÀڽ¹ýÄ¢
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • GnRH agonist
    ¼º¼±ÀÚ±ØÈ£¸£¸ó À¯¸® È£¸£¸ó È¿´É¾à
  • alpha-adrenergic agonist
    ¾ËÆÄ¾Æµå·¹³¯¸°ÃËÁøÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inverse agonist
    ¿ª(¼º)È¿Çö<´É>Á¦.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼ºÃËÁøÁ¦
  • agonist
    ÀÛ¿ëÁ¦(íÂéÄð¥), ÈïºÐÁ¦(ýéÝÇð¥)
  • agonist
    È¿´É¾à(üùÒöå·), È¿ÇöÁ¦(üùúéð¥).
  • alpha-adrenergic agonist
    ¾ËÆÄ¾Æµå·¹³¯¸°ÃËÁøÁ¦
  • cholinergic agonist
    Äݸ°¼º ÃËÁøÁ¦
  • dopamine agonist
    µµÆÄ¹Î È¿ÇöÁ¦(üùúÞð¥)
  • dopamine autoreceptor agonist
    µµÆÄ¹Î ÀÚ°¡¼ö¿ëü È¿ÇöÁ¦
  • muscarinic agonist
    ¹«½ºÄ«¸°¼ºÀÛ¿ëÁ¦
  • opioid agonist
    ¾ÆÆí¾çÀÛ¿ëÁ¦
  • partial agonist
    ºÎºÐÀû ÀÛ¿ë¾à(¡­íÂéÄå·).(¾à¸®)ºÎºÐ(Àû) È¿´É¾à, ºÎºÐ(Àû) È¿ÇöÁ¦.
  • inverse
    µµÄ¡(ÓîöÇ)ÀÇ, µµÂø(Óîó¹)ÀÇ, ¿ª(¼º)(æ½àõ)ÀÇ, ¿ªÀ§(æ½êÈ)ÀÇ, ¿ª(ÀÛ¿ë) ¼º.
  • inverse eruption of teeth
    Ä¡¾Æ¿ª»ý(öÍ䳿½ßæ).
  • inverse form
    ¿ªÇü½Ä(ËçÌ´Ëà).
  • inverse interpolation
    ¿ªº¸°£¹ý(ËçËÓ˧ËÑ).
  • inverse lymph node
    ¿ªÀ§¸²ÇÁÀý
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Inverse lymph node
    ¿ªÀ§¸²ÇÁÀý
    [¿¾ ¿ë¾î] ¿ªÀ§ÀÓÆÄÀý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inverse substrate
    ¿ª ±âÁú(æ½Ðñòõ)
  • agonist
    ÀÛµ¿Ã¼ (íÂÔÑô÷)
  • cholinergic agonist
    Äݸ°ÀÛµ¿Á¦(íÂÔÑð¥)
  • partial agonist
    ºÎºÐ ÀÛµ¿Á¦(Ý»ÝÂíÂÔÑð¥)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IDF inverse document frequency
IRV inferior radicular vein; inspiratory reserve volume; inverse ratio ventilation
IHSS(= HCMP) Idiopathic Hypertrophic Subaortic Stenosis
  = Obstructive Idiopathic Hypertrophic Car...
ORA opiate receptor agonist
PAA partial agonist activity; phenylacetic acid; phosphonoacetic acid; physical abilities analysis; plas...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IPCR Inverse PCR
IPCR Inverse polymerase chain reaction
IRV Inverse ratio ventilation
PC-IRV pressure controlled inverse ratio ventilation
R,S receptor agonist
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • inverse
    µµÄ¡ÀÇ, µµÂøÀÇ, ¿ª¼ºÀÇ, ¿ªÀ§ÀÇ, ¿ªÀۿ뼺
  • inverse eruption of teeth
    Ä¡¾Æ ¿ª»ý
  • inverse stretch reflex
    ¿ª½ÅÀå ¹Ý»ç
  • law of inverse square
    Á¦°öÀÇ ¹ýÄ¢
    Á¶»çÀÇ °­µµ´Â Á¶»ç¼±¿ø°ú ÇÇÁ¶»ç ¸é°úÀÇ °Å¸®ÀÇ Á¦°ö¿¡ ¹Ýºñ·ÊÇÑ´Ù.
  • 2-adrenergic agonist
    2-¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦, 2-¾Æµå·¹³¯¸° ÀÛµ¿Á¦
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼º ÀÛµ¿¾à
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¸¦ ÈïºÐ½ÃÅ´À¸·Î½á È¿°ú¸¦ ³ªÅ¸³»´Â ¾à¹°. ´ë°Ô ¾Æ¹Î È­ÇÕ¹°À̹ǷΠ±³°¨½Å°æ À¯»ç ¾Æ¹ÎÀ̶ó°íµµ ÇÑ´Ù.
  • agonist muscle
    µ¿±Ù±º, ÁÖµ¿±Ù
  • alpha 2 agonist clonidine
    ¾ËÆÄ 2 ÀÛµ¿ Ŭ·Î´Ïµò
  • dopamine autoreceptor agonist
    µµÆÄ¹Î ÀÚ°¡ ¼ö¿ëü È¿ÇöÁ¦
  • high-affinity agonist
    °íģȭ¼º ÀÛ¿ë ¹°Áú
  • opiate agonist alkaloid
    ¾ÆÆí¼º ÀÛµ¿ ¹°Áú ¾ËÄ«·ÎÀ̵å
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
inverse 1. Opposite in order, relation, or effect; reversed; inverted; reciprocal; opposed to direct.
2. <botany> Inverted; having a position or mode of attachment the reverse of that which is usual.
3. <mathematics> Opposite in nature and effect; said with reference to any two operations, which, when both are performed in succession upon any quantity, reproduce that quantity; as, multiplication is the inverse operation to division. The symbol of an inverse operation is the symbol of the direct operation with -1 as an index. Thus sin -1 x means the arc whose sine is x.
<geometry> Inverse figures, two points lying on a line drawn from the center of a fixed circle or sphere, and so related that the product of their distances from the center of the circle or sphere is equal to the square of the radius.
<mathematics> Inverse, or Reciprocal, ratio, the ratio of the reciprocals of two quantities. Inverse, or Reciprocal, proportion, an equality between a direct ratio and a reciprocal ratio; thus, 4: 2:: 1/3: 1/6, or 4: 2:: 3: 6, inversely.
Origin: L. Inversus, p. P. Of invertere: cf. F. Inverse. See Invert.
Source: Websters Dictionary
(01 Mar 1998)
inverse anaphylaxis Anaphylactic shock in an animal (e.g., guinea pig) whose tissues contain Forssman antigen, resulting from an intravenous injection of serum that contains Forssman's antibody.
(05 Mar 2000)
inverse density dependence <epidemiology> See density dependence.
(05 Dec 1998)
inverse ocular bobbing Slow downward eye movement followed by delayed quick upward return.
(05 Mar 2000)
inverse square law As applied to point sources, the intensity of radiation diminishes in proportion to the square of the distance from the source.
(05 Mar 2000)
inverse symmetry Correspondence of the right or left side of an asymmetrical individual to the left or right side of another.
(05 Mar 2000)
inverse syntropy A situation in which the presence of one disease tends to decrease the possibility of another.
(05 Mar 2000)
agonist 1. <anatomy> A prime mover.
2. <pharmacology> A drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances, thus triggering a biochemical response.
(18 Nov 1997)
calcium channel agonist <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues.
This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
(12 Dec 1998)
receptor agonist A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted.
(22 May 1997)
mixed opioid agonist-antagonist <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type.
(13 Nov 1997)
muscarinic agonist Drugs that bind to and activate muscarinic cholinergic receptors (receptors, muscarinic). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate.
(12 Dec 1998)
histamine agonist Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically.
(12 Dec 1998)
opioid agonist <pharmacology> Any morphine-like compound that produces bodily effects including pain relief, sedation, constipation and respiratory depression.
(16 Dec 1997)
opioid partial agonist <pharmacology> A compound that has an affinity for and stimulates physiologic activity at the same cell receptors as opioid agonists but that produces only a partial (i.e., submaximal) bodily response.
(16 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agonist
    ½Î¿ò(°æ±â)ÀÇ °¡´ãÀÚ;(¹®ÇÐ ÀÛǰÀÇ)ÁÖÀΰø;ÁÖµ¿(ÀÛµ¿)±Ù;ÀÛ¿ë(ÀÛµ¿)¾à(¹°Áú)
  • inverse
    ¿ªÀÇ; °Å²Ù·Î µÈ
  • inverse
    ¿ªÀÇ;¹Ý´ë(ÀÇ);°Å²Ù·ÎµÈ;¿ª(ÇÔ)¼öÀÇ;¿ª;¿ª(ÇÔ)¼ö;¹Ý´ë(ÀǰÍ)
  • inverse proportion
    (¼ö)¹Ý¿ªºñ·Ê
  • inverse ratio
    (¼ö)¹Ýºñ;¿ªºñ
  • inverse square law
    (¹°)¿ªÁ¦°ö¹ýÄ¢
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á